Mitomycin Medac (Mitomycin)

Mitomycin is an antineoplastic antibiotic used in intravesical therapy for urothelial malignancies.

• Non‑muscle invasive bladder cancer: reduces tumour recurrence after transurethral resection.
• Upper‑tract urothelial carcinoma: provides bladder‑sparing treatment when administered intravesically.
• Adjunct systemic therapy for solid tumours: used off‑label in combination regimens for gastric, pancreatic or breast cancers.

• Mitomycin exerts its antineoplastic effect by undergoing enzymatic reduction within tumor cells, forming reactive intermediates that create covalent cross‑links between DNA strands. This DNA cross‑linking blocks replication and transcription, leading to inhibition of DNA synthesis and ultimately cell death in rapidly dividing cancer cells.

Mitomycin may cause a range of adverse reactions, from mild irritation to severe systemic toxicity.

Common Side Effects

• Bladder irritation: dysuria, urgency, frequency.
• Hematuria: visible blood in urine.
• Mild nausea or vomiting.
• Fatigue or general weakness.
• Transient low-grade fever.
• Mild electrolyte disturbances.

Serious or Rare Side Effects

• Severe hemorrhagic cystitis.
• Bone‑marrow suppression leading to neutropenia or thrombocytopenia.
• Acute renal toxicity.
• Pulmonary fibrosis or interstitial pneumonitis.
• Anaphylactic or severe allergic reactions.
• Life‑threatening infection due to immunosuppression.

Prior to initiating Mitomycin therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity.

• Renal function assessment: ensure adequate glomerular filtration before intravesical instillation.
• Hematologic monitoring: perform regular complete blood counts to detect marrow suppression.
• Infection risk: avoid use in patients with active urinary or systemic infections.
• Prior bladder surgery: use with caution in individuals with recent instrumentation.
• Catheter technique: follow strict aseptic protocol to prevent contamination.
• Store at room temperature: keep in the original container, protect from moisture and direct light.

Mitomycin can interact with other medicines, altering efficacy or increasing toxicity.

Major Interactions (Avoid)

• Concurrent myelosuppressive chemotherapy: additive bone‑marrow toxicity.
• Nephrotoxic agents (e.g., cisplatin, aminoglycosides): heightened renal injury risk.
• Pelvic radiotherapy: increased risk of severe cystitis.
• Strong CYP450 inhibitors (if applicable): potential accumulation.
• Live vaccines: risk of uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• NSAIDs: may exacerbate renal impairment.
• Anticoagulants/antiplatelet drugs: increased bleeding tendency.
• ACE inhibitors or ARBs: possible additive renal effects.
• Diuretics: may affect fluid balance and renal clearance.
• Hormonal therapies: monitor for overlapping toxicities.